Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cannabics Pharmaceuticals Inc (CNBX)

Cannabics Pharmaceuticals Inc (CNBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies

TEL AVIV, Israel and BETHESDA, Maryland , Oct. 16, 2019 /PRNewswire/ --   Cannabics Pharmaceuticals Inc.  (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot study to test the...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Appoints Company's Founder to Its Board of Directors

TEL AVIV, Israel and BETHESDA, Maryland , Oct. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid based cancer medicine, today announced...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Appoints Company's Founder to Its Board of Directors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid based cancer medicine, today announced that it has appointed the Company's Founder as a new Director and Member of its...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

TEL AVIV , Israel and BETHESDA, Maryland , Sept. 12, 2019 /PRNewswire/ --  Cannabics Pharmaceuticals Inc.  (OTC-QB: CNBX), a leader in personalized cannabis based cancer medicine, today...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX), a leader in personalized cannabis based cancer medicine, today announced that its Scientific Director, Dr. Ilan Hochman, is scheduled to present research...

CNBX : 0.2120 (+1.44%)
Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

Wize Pharma, Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (OTCQB: CNBX)...

WIZP : 0.2500 (+4.17%)
CNBX : 0.2120 (+1.44%)
Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

HOD HASHARON, Israel , June 28, 2019 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced...

CNBX : 0.2120 (+1.44%)
WIZP : 0.2500 (+4.17%)
/C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph,...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Appoints Two Independent Directors

TEL AVIV , Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc.   (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Appoints Two Independent Directors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

TEL AVIV, Israel and BETHESDA, Maryland , May 30, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

TEL AVIV , Israel and BETHESDA, Maryland , April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc.   (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused...

CNBX : 0.2120 (+1.44%)
Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli...

CNBX : 0.2120 (+1.44%)
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

ACRGF : 5.9100 (-1.01%)
ALEAF : 0.6040 (-6.34%)
ARREF : 0.6000 (+3.45%)
CWBHF : 13.3371 (-0.10%)
CORVF : 1.5100 (+1.34%)
CRLBF : 6.2070 (-1.67%)
DYAI : 6.59 (+1.70%)
ELLXF : 1.4500 (+1.40%)
EMHTF : 0.7147 (+2.10%)
GLDLF : 0.8000 (-0.56%)
GTBIF : 9.0050 (-2.75%)
GRWG : 3.9700 (-0.75%)
HEOFF : 0.9448 (+2.70%)
ITHUF : 1.7700 (+14.94%)
IMLFF : 0.2034 (-7.55%)
ISYRF : 1.0100 (-12.17%)
MMNFF : 1.0800 (unch)
MTAFF : 1.0300 (+0.98%)
MJARF : 0.4660 (-3.66%)
NUPMF : 3.4700 (-1.14%)
NLST : 0.3276 (+1.11%)
STLHF : 0.5324 (-0.69%)
TRLFF : 0.1402 (+0.21%)
AITB : 5.24 (+2.34%)
ALYE : 2.5550 (-5.37%)
ARTH : 0.1630 (+0.06%)
ARHH : 1.2600 (-2.05%)
ATEA : 11.5000 (unch)
BICXD : 4.5400 (-9.02%)
BRTI : 0.1899 (-9.57%)
CNBX : 0.2120 (+1.44%)
CLOK : 0.8500 (-5.56%)
CVSI : 2.0800 (-4.59%)
DUOT : 0.5200 (+10.64%)
EVLLF : 1.0300 (+7.29%)
FLUX : 9.8000 (+0.51%)
GBPT : 7.0000 (-12.50%)
GTBP : 0.1900 (+18.75%)
KSHB : 1.2700 (-5.22%)
MRMD : 0.7710 (+4.19%)
MLCPF : 3.5200 (+11.47%)
MRIC : 4.17 (+0.97%)
NMUS : 0.6500 (-9.52%)
NWGI : 0.3900 (-6.14%)
OWCP : 0.0080 (unch)
PPCB : 0.9250 (+11.45%)
QBIO : 0.4190 (-2.56%)
RSSS : 2.3000 (-4.17%)
VTLR : 0.0727 (-4.47%)
WIZD : 0.0999 (+8.00%)
OTCM : 34.2800 (+0.06%)
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma,...

CNBX : 0.2120 (+1.44%)
WIZP : 0.2500 (+4.17%)
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its...

CNBX : 0.2120 (+1.44%)
WIZP : 0.2500 (+4.17%)
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company closed a deal...

WIZP : 0.2500 (+4.17%)
CNBX : 0.2120 (+1.44%)
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

CNBX : 0.2120 (+1.44%)
WIZP : 0.2500 (+4.17%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -0.64 , AIZ +1.71 , SBAC +1.27 , SO +0.40 , WELL -0.08
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar